<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16664">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948609</url>
  </required_header>
  <id_info>
    <org_study_id>13-11221</org_study_id>
    <nct_id>NCT01948609</nct_id>
  </id_info>
  <brief_title>Prospective Research of Outcomes After Salpingo-oophorectomy</brief_title>
  <acronym>PROSper</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROSper is a prospective cohort study of 100 women 35-50 years of age with BRCA 1/2
      mutations who have elected to either undergo risk reducing salpingo-oophorectomy (RRSO) or
      nonsurgical management. The investigators will compare the change in cardiovascular health,
      bone health, sexual function, quality of life, and menopausal symptoms over 3 years of
      follow-up between women who undergo RRSO (baseline just prior to surgery) and age-matched
      controls that do not undergo RRSO.

      The investigators hypothesis is that women who undergo a premature surgical menopause
      induced by RRSO have worse cardiovascular health and bone health compared with women who do
      not undergo RRSO.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change from baseline in risk of cardiovascular disease and osteoporosis at 36 months.</measure>
    <time_frame>Baseline to 36 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will use dual-energy x-ray absorptiometry (DEXA) scan results and Intima-media thickness of the carotid artery (IMT) testing to assess changes in bone mineral density and carotid artery intima media thickness, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline sexual functioning and quality of life at 36 months.</measure>
    <time_frame>Baseline to 36 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will use standard questionnaires to assess changes in overall quality of life and sexual function.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>BRCA1 Gene Mutation</condition>
  <condition>BRCA2 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Treated with RRSO</arm_group_label>
    <description>Women with the BRCA gene 1/2 mutation who choose to undergo risk reducing salpingo-oophorectomy (RRSO) treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No RRSO treatment</arm_group_label>
    <description>Women with the BRCA gene 1/2 mutation who choose non-surgical treatment.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood; serum; EDTA Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be women 35-50 years old with a confirmed diagnosis of a
        deleterious BRCA 1/2 mutation recruited through UCSF.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BRCA mutation 1/2 or &quot;Variant suspected deleterious&quot; mutation.

          -  Female

          -  Age 35-50 years

          -  Able to undergo RRSO

          -  Speaks English

          -  Able to give informed consent

        Exclusion Criteria:

          -  Prior history of bilateral oophorectomy

          -  BRCA 1/2 deleterious mutation

          -  Plans to move out of geographic region in next 3 years

          -  Unable to travel to study visits
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Jacoby, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Lemp</last_name>
    <phone>415-297-3114</phone>
    <email>LempS@obgyn.ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Lemp</last_name>
      <phone>415-297-3114</phone>
      <email>LempS@obgyn.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Vanessa Jacoby, MD, MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 16, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
